BEATWNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as BEAT
HeartBeam, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.02+0.02 (+551.61%)
Close on Oct 19, 2026
- Market cap
- $1.07M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1M
Shares held, 13F filers
Institutional holders
6
0 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
9 buys · 3 sales
Net sold $126.09K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Strome Mark E | 3,764,200 | 6.80% | 13D (active) amendment | Apr 16, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BEATW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 500,000 | – | $14.00K | – | 0.00% |
| Clear Street Group Inc. | 16,611 | – | $465 | – | 0.00% |
| D'Orazio & Associates, Inc. | 16,000 | – | $453 | – | 0.00% |
| Two Sigma Securities, LLC | 11,653 | – | $330 | −246 | 0.00% |
| Wells Fargo & Company/Mn | 7,500 | – | $210 | – | 0.00% |
| UBS Group AG | 3,837 | – | $107 | +1,880 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 6 | 1M | 0 / 1 | 1 / 0 | 0M | 0M |
| Q1 2026 | 6 | 1M | 0 / 3 | 0 / 0 | 0M | 0M |
| Q4 2025 | 6 | 1M | 2 / 1 | 1 / 2 | 0M | 0M |
| Q3 2025 | 6 | 1M | 1 / 0 | 2 / 0 | 0M | 0M |
| Q2 2025 | 6 | 1M | 1 / 0 | 1 / 0 | 0M | 0M |
| Q1 2025 | 5 | 1M | 0 / 1 | 0 / 0 | 0M | 0M |
| Q4 2024 | 5 | 1M | 0 / 0 | 1 / 0 | 0M | 0M |
| Q3 2024 | 5 | 1M | 1 / 1 | 1 / 0 | 0M | 0M |
| Q2 2024 | 4 | 1M | 0 / 1 | 1 / 3 | 0M | 0M |
| Q1 2024 | 7 | 1M | 3 / 2 | 0 / 0 | 0M | 0M |
| Q4 2023 | 4 | 1M | 0 / 0 | 2 / 2 | 0M | 0M |
| Q3 2023 | 7 | 1M | 2 / 0 | 2 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Branislav Vajdic | President, Director | 3,970,784 | Jul 24, 2026 |
| Tim Cruickshank | CFO | 239,990 | Jul 24, 2026 |
| Kenneth Harry Persen | Chief Technology Officer | 448,290 | Jul 24, 2026 |
| Robert Paul ENO | President | 36,742 | Apr 16, 2026 |
| Richard Ferrari | Director | 352,289 | Apr 24, 2026 |
| Michael R. Jaff | Director | 127,059 | Apr 16, 2026 |
| Marga Ortigas-Wedekind | Director | 154,117 | Apr 16, 2026 |
| Mark E. Strome | Director | 3,707,146 | Apr 16, 2026 |
| Willem Elfrink | Director | 645,492 | Apr 16, 2026 |
| Kenneth Warwick Nelson III | Director | 144,388 | Mar 23, 2026 |
| Urioste George de | Director | 0 | Mar 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Tim Cruickshank CFO | Jul 24, 2026 | Award | +167,760 | – | – | 239,990 |
| Kenneth Harry Persen Chief Technology Officer | Jul 24, 2026 | Award | +105,740 | – | – | 448,290 |
| Branislav Vajdic President, Director | Jul 24, 2026 | Award | +260,870 | – | – | 3,970,784 |
| Branislav Vajdic President, Director | Jun 15, 2026 | Award | +2,800,000 | – | – | 3,709,914 |
| Richard Ferrari Director | Apr 16, 2026 | Buy | +57,500 | $0.80 | $46.00K | 286,636 |
| Richard Ferrari Director | Apr 16, 2026 | Buy | +62,500 | $0.80 | $50.00K | 291,636 |
| Tim Cruickshank CFO | Apr 16, 2026 | Buy | +31,250 | $0.80 | $25.00K | 72,230 |
| Branislav Vajdic Director | Apr 16, 2026 | Buy | +31,250 | $0.80 | $25.00K | 909,914 |
| Marga Ortigas-Wedekind Director | Apr 16, 2026 | Buy | +25,000 | $0.80 | $20.00K | 137,293 |
| Willem Elfrink Director | Apr 16, 2026 | Buy | +187,500 | $0.80 | $150.00K | 538,667 |
| Mark E. Strome Director | Apr 16, 2026 | Buy | +750,000 | $0.80 | $600.00K | 3,650,000 |
| Robert Paul ENO President | Apr 16, 2026 | Buy | +12,500 | $0.80 | $10.00K | 36,742 |
| Michael R. Jaff Director | Apr 16, 2026 | Buy | +31,250 | $0.80 | $25.00K | 31,250 |
| Michael R. Jaff Director | Feb 9, 2026 | Award | +20,689 | – | – | 95,809 |
| Kenneth Warwick Nelson III Director | Feb 9, 2026 | Award | +17,241 | – | – | 144,388 |
| Richard Ferrari Director | Feb 9, 2026 | Award | +50,000 | – | – | 229,136 |
| Urioste George de Director | Dec 18, 2025 | Sale | −33,185 | $2.83 | $93.91K | 0 |
| Mark E. Strome 10% owner | Dec 17, 2025 | Sale | −250,000 | $3.58 | $895.00K | 2,900,000 |
| Urioste George de Director | Dec 17, 2025 | Sale | −23,961 | $3.68 | $88.18K | 33,185 |
| Richard Ferrari Director | Feb 14, 2025 | Buy | +29,412 | $1.70 | $50.00K | 179,136 |
| Tim Cruickshank CFO | Feb 14, 2025 | Buy | +17,647 | $1.70 | $30.00K | 17,647 |
| Urioste George de Director | Sep 6, 2024 | Sale | −1,674 | $2.34 | $3.92K | 57,146 |
| Urioste George de Director | Aug 30, 2024 | Sale | −5,500 | $2.31 | $12.71K | 58,820 |
| Urioste George de Director | Aug 27, 2024 | Sale | −2,194 | $2.26 | $4.96K | 64,320 |
| Urioste George de Director | Aug 26, 2024 | Sale | −300 | $2.38 | $714 | 66,514 |
| Urioste George de Director | Aug 23, 2024 | Sale | −2,500 | $2.30 | $5.75K | 66,814 |
| Michael R. Jaff Director | Jun 12, 2024 | Award | +33,185 | – | – | 75,120 |
| Willem Elfrink Director | Jun 12, 2024 | Award | +33,185 | – | – | 317,982 |
| Urioste George de Director | Jun 12, 2024 | Award | +33,185 | – | – | 69,314 |
| Richard Ferrari Director | Jun 12, 2024 | Award | +44,247 | – | – | 149,724 |
| Kenneth Warwick Nelson III Director | Jun 12, 2024 | Award | +33,185 | – | – | 127,147 |
| Mark E. Strome 10% owner | Jun 12, 2024 | Award | +33,185 | – | – | 57,146 |
| Marga Ortigas-Wedekind Director | Jun 12, 2024 | Award | +33,185 | – | – | 112,293 |
| Urioste George de Director | Sep 29, 2023 | Sale | −5,500 | $2.06 | $11.33K | 36,129 |
| Urioste George de Director | Sep 28, 2023 | Sale | −8,000 | $2.04 | $16.32K | 41,629 |
| Urioste George de Director | Sep 27, 2023 | Sale | −1,834 | $2.11 | $3.87K | 49,629 |
| Urioste George de Director | Sep 26, 2023 | Sale | −5,000 | $2.09 | $10.45K | 51,463 |
| Urioste George de Director | Sep 22, 2023 | Sale | −2,393 | $2.21 | $5.29K | 56,463 |
| Urioste George de Director | Sep 21, 2023 | Sale | −100 | $2.41 | $241 | 58,856 |
| Urioste George de Director | Sep 20, 2023 | Sale | −883 | $2.46 | $2.17K | 58,956 |
| Urioste George de Director | Sep 18, 2023 | Sale | −5,000 | $2.46 | $12.30K | 59,839 |
| Urioste George de Director | Sep 15, 2023 | Sale | −4,269 | $2.43 | $10.37K | 64,839 |
| Urioste George de Director | Sep 14, 2023 | Sale | −5,000 | $2.17 | $10.85K | 69,108 |
| Urioste George de Director | Sep 13, 2023 | Sale | −3,122 | $1.95 | $6.09K | 74,108 |
| Urioste George de Director | Sep 13, 2023 | Sale | −1,878 | $1.90 | $3.57K | 77,230 |
| Willem Elfrink Director | Jul 13, 2023 | Award | +23,961 | – | – | 284,797 |
| Richard Ferrari Director | Jul 13, 2023 | Award | +31,948 | – | – | 105,477 |
| Mark E. Strome 10% owner | Jul 13, 2023 | Award | +23,961 | – | – | 23,961 |
| Urioste George de Director | Jul 13, 2023 | Award | +23,961 | – | – | 79,108 |
| Marga Ortigas-Wedekind Director | Jul 13, 2023 | Award | +23,961 | – | – | 79,108 |
| Kenneth Warwick Nelson III Director | Jul 13, 2023 | Award | +23,961 | – | – | 93,962 |
| Branislav Vajdic CHIEF EXECUTIVE OFFICER | Feb 10, 2023 | Option exercise | +1,287 | – | – | 911,391 |
| Richard Brounstein Chief Financial Officer | Feb 10, 2023 | Option exercise | +184 | – | – | 112,108 |
| Willem Elfrink Director | Feb 9, 2023 | Conversion | +3,640 | $2.75 | $10.01K | 316,150 |
| Willem Elfrink Director | Feb 9, 2023 | Returned to company | −125,351 | – | – | 312,510 |
| Richard Brounstein Chief Financial Officer | Dec 2, 2022 | Option exercise | +760 | – | – | 111,924 |
| Richard Brounstein Chief Financial Officer | Nov 2, 2022 | Option exercise | +759 | – | – | 111,164 |
| Richard Brounstein Chief Financial Officer | Oct 2, 2022 | Option exercise | +760 | – | – | 110,405 |
| Richard Brounstein Chief Financial Officer | Sep 2, 2022 | Option exercise | +757 | – | – | 109,645 |
| Richard Brounstein Chief Financial Officer | Aug 1, 2022 | Option exercise | +757 | – | – | 108,888 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.